The human immunodeficiency virus (HIV) remains an ongoing global pandemic. There is currently no cure for HIV, but antiretroviral therapies can keep the virus in check and allow individuals with HIV to live longer, healthier lives. These drugs work in two ways. They block the ability of the virus to multiply and they allow numbers of an important type of infection-fighting cell called CD4+ T cells to rebound.

As more patients with HIV survive and transition from one life stage to the next, it is critical to understand how long-term antiretroviral therapies will affect normal age-related changes in their immune systems. The health of an immune system can be evaluated by looking at the number of CD4+ T cells an individual has, though this will vary by age and location. Clinicians use the same metrics to assess the immune health of individuals with HIV, however, as they age, it becomes a challenge to identify if a patient’s immune system recovers normally or insufficiently. Thus, learning more about age-related differences in CD4+ T cells in people living with HIV may help improve their care.

Using data from 1,616 children and 14,542 adults from South Africa, Ujeneza et al. created a simple mathematical model that can compare the immune system of person with HIV with the immune system of a similarly aged healthy individual. The model shows that among individuals with HIV receiving antiretroviral therapies, children have CD4+ T-cell numbers that are closest to the numbers seen in healthy individuals of the same age. This suggests that children may be more able to recover immune system function than adults after beginning treatment. Children also start antiretroviral therapies before their immune system has been severely damaged, while adults tend to start treatment much later when they have fewer CD4+ T cells left.

Ujeneza et al. show that the fewer CD4+ T cells a person has when they start treatment, the faster the number of these cells grows after starting treatment. This suggests that the more damaged the immune system is, the harder it works to recover. This reinforces the need to identify people infected with HIV as soon as possible through testing and to begin treatment promptly. The new model may help clinicians and policy makers develop screening and treatment protocols tailored to the specific needs of children and adults living with HIV.

The efficacy with which antiretroviral therapy (ART) suppresses HIV viral load and restores lymphocyte responses to pathogen-derived antigens, normally lost due to viral replication, is well established (Cooney, 2002; Autran et al., 1997). Following ART initiation, for the majority of HIV-infected individuals, the CD4+ T-cell counts rapidly increase for approximately 4–6 months (Lawn et al., 2006), followed by a slower increase in the next 2–4 years, after which cell numbers plateau (Pinzone et al., 2012). Despite the successes of ART, several studies have demonstrated that large proportions of patients experience incomplete immune restoration following treatment initiation. In Sub-Saharan Africa, approximately 10–16% of children on ART (Mutwa et al., 2014) and variable proportions of adults (Barth et al., 2011; Fatti et al., 2014; Mee et al., 2008) fail to suppress viral load within 12 months of ART initiation. Further, among those that do suppress viral load, many are suboptimal immunological responders (35–40%), that is, they do not reach a CD4+ T-cell count greater than 500 cells/µL within 5 years (Nakanjako, 2016; Swiss HIV Cohort Study et al., 2005). Some patients demonstrate no improvement at all (Lawn et al., 2006).

A variety of statistical methods have been used to model the recovery of CD4+ T-cell counts after ART initiation. A prior review of sub-Saharan African studies of this type established that generalized linear mixed models and generalized estimating equations were most commonly used (Sempa et al., 2017). However, such models are not ‘mechanistic’, in the sense that they make no assumptions regarding the underlying biological processes involved in CD4+ T-cell reconstitution. For this reason, these methods do not allow inferences regarding the dynamics of CD4+ recovery. Recent studies have employed an asymptotic ‘semi-mechanistic’ mixed model to describe CD4+ count recovery in children (Lewis et al., 2012; ARROW Trial Team et al., 2013; Lewis et al., 2017; De Beaudrap et al., 2008) and adults (ANRS 1215/90 Study Group et al., 2009; Means et al., 2016). These models simply assume that CD4+ T-cell counts follow an asymptotic recovery process in all patients. However, it has been demonstrated that in patients with suboptimal or no immune recovery, response trajectories do not follow this profile (ARROW Trial Team et al., 2013). Complicating this picture, diverse CD4+ T-cell count variable transformations were applied, different demographic groups were studied and there is large natural variability of such cell counts across different population groups (Schaberg et al., 1997; Abuye et al., 2005; Maini et al., 1996). As a result, these models do not allow for comparisons across heterogeneous groups of individuals.

In this study, we present a novel mechanistic model that describes the dynamics of CD4+ T-cell count responses in HIV-infected individuals relative to those of healthy individuals. We use nonlinear mixed modelling methods and data from large cohorts of adults and children in South Africa. We assess the generalizability of this model from children to adults. We compare it to the previously published asymptotic model and investigate the impact of demographic and clinical characteristics on long-term immune outcomes.

Methodology

ART patient data

De-identified longitudinal data from HIV-infected patients receiving ART in 13 South African cohorts was provided by the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) (https://www.iedea-sa.org/) (ART-LINC Collaboration of IeDEA et al., 2008; IeDEA and COHERE Cohort Collaborations and Anderegg, 2018). The initial data set was composed of 2,858,743 CD4+ count observations for 223,688 patients of whom 202,108 were adults, 21,267 were children and 313 had no recorded date of birth or date of ART initiation. Children were defined as those aged 17 or younger at treatment initiation. After removing observations that were unrealistic (outside plausible biological ranges) or missing date of measurement, 189,647 adults and 19,060 children remained (Figure 1).

Figure 1

Download asset Open asset

‘Ratio’ model construction

The ratio model relates the CD4+ T-cell dynamics from HIV+ individuals to those of healthy individuals. We first defined, then merged, separate models for each group, using the logistic growth model. This model assumes that a given quantity grows exponentially until it approaches a constant carrying capacity k (Figure 2), or limit, to represent the dynamics of the immune system. This concept has been used in prior studies to describe the proliferation rate of CD4+ T-cells for individuals on therapy (Kaufmann et al., 2001; Di Mascio et al., 2006). We denote the CD4+ T-cell count ‘growth’ (or regeneration) rate of an individual on ART by $r$, and the ‘environmental’ (or physiological) carrying capacity by $k$, which can be thought of as the maximal number of CD4+ T-cells that can be sustained by all available biological resources.

Figure 2

Download asset Open asset

Figure 2—source data 1

Data source to reproduce the plot for the logistic growth model.

https://cdn.elifesciences.org/articles/42390/elife-42390-fig2-data1-v2.txt

Download elife-42390-fig2-data1-v2.txt

For HIV-infected people, the rate of change of CD4+ T-cells $x,$ per $\mu L$ per unit time, $t,$ is expressed by the following ordinary differential equation:

(1) $\frac{dx}{dt}=rx\left(1-\frac{x}{k}\right),$

where $t$ starts at ART initiation. The theoretical growth rate $r$ is actually an effective rate, a constant obtained by taking the average of the growth rate at different time points. This ‘instant’ growth rate increases for values of $x$ smaller than the inflexion point $k/2$ and starts decreasing thereafter, as the value of $x$ approaches the carrying capacity $k$.

The solution to Equation 1 gives the expression for CD4+ T-cell counts per $\mu L$ at time $t$ as:

(2) $x\left(t\right)=k{e}^{rt}\frac{1}{\frac{k-x_0}{x_0}+e^{rt}},$

where $x_0\mathrm{}$ is the CD4+ T-cell count of the individual, at ART initiation.

A study on healthy South African population showed that their CD4+ counts increased from young adulthood until about 70 years of age (Malaza et al., 2013). Thus, we can also describe the CD4+ T-cell counts in a healthy individual $y\left(t\right)\mathrm{}$ at time $t$, as:

(3) $y\left(t\right)=q{e}^{st}\frac{1}{\frac{q-y_0}{y_0}+e^{st}},$

where $s$ is the CD4+ T-cell growth rate,$q$ the carrying capacity, and time $t$ has an origin equivalent to ART initiation in an age-matched HIV infected patient. Thus, the equation describes the immune system dynamics of the healthy individual, starting from when they have a similar age as their corresponding HIV-infected counterpart.

The ‘Ratio’ model is then defined by dividing Equation 2 by Equation 3, substituting $z_0=\frac{x_0}{y_0},K=\raisebox{1ex}{$k$}\!\left/ \!\raisebox{-1ex}{$x_0$}\right.$, and $Q=\raisebox{1ex}{$q$}\!\left/ \!\raisebox{-1ex}{$y_0$}\right.$, and simplifying to obtain, $z\left(t\right)$, the scaled CD4+ T-cell count at time $t$:

(4) $z\left(t\right)=z_0\frac{K}{Q}\frac{1+e^{-st}\left(Q-1\right)}{1+e^{-rt}\left(K-1\right)},$

where $K$ and $Q$ are the CD4+ T-cell scaled carrying capacities of an HIV-infected and a healthy age-matched individual, respectively; and $z_0$ the ratio of the baseline CD4+ T-cell count of the HIV-infected individuals to that of the healthy individual, in order words, the baseline scaled CD4+ T-cell counts. An implication of this model is that when the value of $K$ is close to unity, the patient’s long-term carrying capacity is approaching the particular patient’s ‘homeostatic optimum’ for CD4+ T-cell counts, that is, the amount of CD4 cells that can be sustained by the available biological resources. In this case a subsequent increase in CD4+ T-cell counts would be unlikely. Further, associated with an ‘immune set-point’ achieved in healthy adults their value of $Q$ would tend to unity. In healthy children, this is not so owing to growth, that is, their CD4+ T-cell count changes with the increase of their total blood volume (Bains et al., 2009). Thus, their value of $Q$ is expected to be less than one.

Additionally, a baseline scaled CD4+ T-cell count of 1 means that the individual started therapy with a normal CD4+ T-cell count for their age, while a value smaller than one indicates that an individual started therapy with a lower CD4+ count compared with those of healthy individuals of the same age. Note that both growth rates for HIV-infected and healthy individuals are the same (unchanged), from the original logistic growth models to the ‘ratio’ model. A table indicating the ranges for each parameter is available in Supplementary file 1.

Model fitting techniques

We used nonlinear mixed effects techniques (NLMM) to fit all models to data. NLMMs are characterized by two main components: a fixed effect part that describes the population mean, and the random effects that describe individual subjects' deviations from the mean. If we denote by $\theta$ the vector of population estimates, and by $b_i$ the matrix of the random effects’ estimates, a general mathematical description of NLMM for continuous variables is given by,

(5) ${\displaystyle z_{i,j}=f(p_{i,j},\theta ,b_i)+g(p_{i,j},\theta ,b_i,\gamma ){ϵ}_{i,j},1\le i\le N,1\le j\le n_i,}$

where $z_{i,j}$ is the scaled CD4+ T-cell counts of patient $i$ at time $j;$ function $f$ is the nonlinear model of interest and $g$ is the structure of the error model; $N$ is the total number of subjects and $n_i$ the number of observations $j$ for each subject $i$. Both $f$ and $g$ depend on the predictor variables $p_{i,j}$, the population parameters $\theta$, and the random effects $b_i$. In addition, the function $g$ depends on the form chosen for the error model, which is governed by a set of parameters $\gamma .$ In this study, we used a proportional error model, such that ${\displaystyle g=df}$ and $\gamma =d$ (single constant parameter $d$), and Equation 4 as our basis function $f$:

(6) ${\displaystyle z_{i,j}=z_{0_i}\frac{K_i}{Q_i}\frac{1+\left(Q_i-1\right)e^{-s_i{t}_{i,j}}}{1+\left(K_i-1\right)e^{-r_i{t}_{i,j}}}\times (1+d{ϵ}_{i,j}),1\le i\le N,0\le j\le n_i.}$

For purposes of comparison, we also applied the same NLMM methodology to an ‘asymptotic’ model, similar to that previously described (Lewis et al., 2012), such that,

(7) $z_{i,j}={(\mathrm{A}\mathrm{s}\mathrm{y}\mathrm{m}}_i-\left({\mathrm{A}\mathrm{s}\mathrm{y}\mathrm{m}}_i-{\mathrm{R}0}_i\right)e^{{c_{i}t}_{i,j}})\times (1+d{\epsilon }_{i,j}),1\le i\le N,0\le j\le n_i,$

where ${\mathrm{A}\mathrm{s}\mathrm{y}\mathrm{m}}_i$ is the value of the asymptote for patient $i$, ${\mathrm{R}0}_i$ their intercept, and $c_i$ their logarithm of rate of increase of scaled CD4+ T-cell counts. The term $\left({\mathrm{A}\mathrm{s}\mathrm{y}\mathrm{m}}_i-{\mathrm{R}0}_i\right)$ represents the scaled increase of CD4+ T-cells following ART initiation.

The NLMM method assumes that the random effects are normally distributed, with mean zero and variance-covariance matrix $\mathrm{\Omega }$:$b_i~\aleph (0,\mathrm{\Omega })$; and the errors ${\epsilon }_{i,j}$ are also normally distributed with mean zero and variance 1: ${\epsilon }_{i,j}~\aleph \left(\mathrm{0,1}\right)$. These represent noise and errors in the data. The individual parameters (denoted by a matrix ${\psi }_i$) are given by ${\psi }_i=\theta C_i+b_i$, with $C_i$ the matrix of individual covariates. A demo code is available through a github repository (https://github.com/EvaLiliane/RM_Code_eLife [copy archived at swh:1:rev:624ff31c5fc969885f29b7291ee06886d24c64f7]; Ujeneza, 2020).

Additional considerations

Final adjusted models were obtained using a backward–forward stepwise approach using p-value criterion for covariate inclusion and AIC, BIC for the overall models. To evaluate the robustness of our results, we compared the estimated parameters of the full analysis described above using only three covariates: sex, baseline age, and baseline viral load, with those from models with all covariates.

All graphs and computations were produced in the statistical environment R (R Development Core Team, 2017). Nonlinear mixed model fitting employed the saemix R package (Comets et al., 2005), which uses a stochastic approximation, expectation-maximization algorithm for parameter estimation. All final adult and children models (Figures 3 and 4) converged relatively rapidly towards their estimated values, as shown by the log-likelihood graphs (Figure 3—figure supplement 1 and Figure 4—figure supplement 1). Even when initial values were marginally varied, the final models converged to similar estimates.

Figure 3 with 2 supplements see all

Download asset Open asset

Figure 3—source data 1

Data source to reproduce the population-level CD4 trajectories plot for children.

https://cdn.elifesciences.org/articles/42390/elife-42390-fig3-data1-v2.txt

Download elife-42390-fig3-data1-v2.txt

Figure 4 with 2 supplements see all

Download asset Open asset

Figure 4—source data 1

Data source to reproduce the population-level CD4 trajectories plot for adults.

https://cdn.elifesciences.org/articles/42390/elife-42390-fig4-data1-v2.txt

Download elife-42390-fig4-data1-v2.txt

CD4+ T-cell count remains the main proxy used to evaluate the long-term effects of ART on the immune system. Understanding its dynamics is crucial, to ensure that the best care is delivered to HIV-infected patients. Although previous studies described CD4+ T-cell count dynamics in HIV-treated patients, using non-mechanistic (Sempa et al., 2017) and mechanistic models (Lewis et al., 2012; Means et al., 2016; Di Mascio et al., 2006), none provided a method that allows for direct comparison with age-matched healthy controls. This study proposes a mechanistic model for the immune system reconstitution, which relates CD4+ T-cells count of an individual on ART with that of a healthy individual with similar characteristics. We demonstrate that CD4+ T-cell growth rates are higher in HIV-treated patients than in healthy individuals and that age has opposite effects on CD4+ counts dynamics in HIV-treated children, compared to healthy children. This model was compared to the asymptotic model, previously used to model CD4+ T-cell trajectories after ART initiation, under two different scenarios: estimating baseline scaled CD4+ T-cell count (scenario 1) and using it as a predictor (scenario 2). Moreover, this study is the first of its kind in evaluating large samples of children and adults data in a comparative way.

Corbeau and Reynes, 2011 have described the three phases of CD4+ counts recovery in HIV-treated patients: a sharp increase in the first 1–6 months, a still high increase up to 2 years, and a slow gradual increase that goes on beyond 4 years of therapy. Our results show that though both the ratio and asymptotic model predict similar scaled baseline CD4+ counts, only the ratio model is able to reproduce these three phases of immune reconstitution. Thus, it is likely to be better in accurately predicting the long-term behaviour of CD4+ T-cell counts trajectory. Furthermore, the ratio model is derived directly from the logistic growth model which describes a known biological process, and as such, CD4+ T-cells growth rate $r$ is directly relatable to the average of the actual increase of CD4+ T-cells per month over the observation period.

Data used are from the International Epidemiologic Databases to Evaluate AIDS Southern Africa collaboration. They maintain a database of routinely collected data from various clinics, mostly located in South Africa. We recommend that interested readers contact Dr Morna Cornell, Project Manager IeDEA-SA in Cape Town (morna.cornell@uct.ac.za) to establish a data-sharing agreement. A research proposal highlighting how the data will be used is required. Source data for figures and figure supplements are provided, and the source code is available at https://github.com/EvaLiliane/RM_Code_eLife copy archived at https://archive.softwareheritage.org/swh:1:rev:624ff31c5fc969885f29b7291ee06886d24c64f7/.

1. 1. Abuye C
   2. Tsegaye A
   3. West CE
   4. Versloot P
   5. Sanders EJ
   6. Wolday D
   7. Hamann D
   8. De Wit TF
   9. Fontanet AL

   (2005) Determinants of CD4 counts among HIV-negative ethiopians: role of body mass index, gender, cigarette smoking, khat (Catha edulis) chewing, and possibly altitude?

   Journal of Clinical Immunology 25:127–133.

   https://doi.org/10.1007/s10875-005-2818-y

   • PubMed
   • Google Scholar
2. 1. ANRS 1215/90 Study Group
   2. De Beaudrap P
   3. Etard JF
   4. Diouf A
   5. Ndiaye I
   6. Guèye NF
   7. Guèye PM
   8. Sow PS
   9. Mboup S
   10. Ndoye I
   11. Ecochard R
   12. Eric D

   (2009) Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal

   The American Journal of Tropical Medicine and Hygiene 80:1047–1053.

   https://doi.org/10.4269/ajtmh.2009.80.1047

   • PubMed
   • Google Scholar
3. 1. ARROW Trial Team
   2. Picat MQ
   3. Lewis J
   4. Musiime V
   5. Prendergast A
   6. Nathoo K
   7. Kekitiinwa A
   8. Nahirya Ntege P
   9. Gibb DM
   10. Thiebaut R
   11. Walker AS
   12. Klein N
   13. Callard R

   (2013) Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan africa: a cohort-based modelling study

   PLOS Medicine 10:e1001542.

   https://doi.org/10.1371/journal.pmed.1001542

   • PubMed
   • Google Scholar
4. 1. ART-LINC Collaboration of IeDEA
   2. Nash D
   3. Katyal M
   4. Brinkhof MW
   5. Keiser O
   6. May M
   7. Hughes R
   8. Dabis F
   9. Wood R
   10. Sprinz E
   11. Schechter M
   12. Egger M

   (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies

   Aids 22:2291–2302.

   https://doi.org/10.1097/QAD.0b013e3283121ca9

   • PubMed
   • Google Scholar
5. 1. Autran B
   2. Carcelain G
   3. Li TS
   4. Blanc C
   5. Mathez D
   6. Tubiana R
   7. Katlama C
   8. Debré P
   9. Leibowitch J

   (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

   Science 277:112–116.

   https://doi.org/10.1126/science.277.5322.112

   • PubMed
   • Google Scholar
6. 1. Autran B

   (1999) Restoration of the immune system with anti-retroviral therapy

   Immunology Letters 66:207–211.

   https://doi.org/10.1016/S0165-2478(98)00159-X

   • Google Scholar
7. 1. Bains I
   2. Antia R
   3. Callard R
   4. Yates AJ

   (2009) Quantifying the development of the peripheral naive CD4+ T-cell pool in humans

   Blood 113:5480–5487.

   https://doi.org/10.1182/blood-2008-10-184184

   • PubMed
   • Google Scholar
8. 1. Bajaria SH
   2. Webb G
   3. Cloyd M
   4. Kirschner D

   (2002) Dynamics of naive and memory CD4+ T lymphocytes in HIV-1 disease progression

   JAIDS Journal of Acquired Immune Deficiency Syndromes 30:41–58.

   https://doi.org/10.1097/00042560-200205010-00006

   • PubMed
   • Google Scholar
9. 1. Barth RE
   2. Tempelman HA
   3. Moraba R
   4. Hoepelman AI

   (2011) Long-Term outcome of an HIV-Treatment programme in rural africa: viral suppression despite early mortality

   AIDS Research and Treatment 2011:1–5.

   https://doi.org/10.1155/2011/434375

   • PubMed
   • Google Scholar
10. Software

    1. Comets E
    2. Lavenu A
    3. Lavielle M

    (2005)

    SAEMIX, an R Version of the SAEM Algorithm 20th Meet

    SAEMIX, an R Version of the SAEM Algorithm 20th Meet.
11. 1. Comets E
    2. Lavenu A
    3. Lavielle M

    (2017) Parameter estimation in nonlinear mixed effect models using saemix, an R implementation of the SAEM algorithm

    Journal of Statistical Software 80:i03.

    https://doi.org/10.18637/jss.v080.i03

    • Google Scholar
12. 1. Cooney EL

    (2002) Clinical indicators of immune restoration following highly active antiretroviral therapy

    Clinical Infectious Diseases 34:224–233.

    https://doi.org/10.1086/323898

    • PubMed
    • Google Scholar
13. 1. Corbeau P
    2. Reynes J

    (2011) Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection

    Blood 117:5582–5590.

    https://doi.org/10.1182/blood-2010-12-322453

    • PubMed
    • Google Scholar
14. 1. Cornell M
    2. Schomaker M
    3. Garone DB
    4. Giddy J
    5. Hoffmann CJ
    6. Lessells R
    7. Maskew M
    8. Prozesky H
    9. Wood R
    10. Johnson LF
    11. Egger M
    12. Boulle A
    13. Myer L
    14. International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration

    (2012) Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study

    PLOS Medicine 9:e1001304.

    https://doi.org/10.1371/journal.pmed.1001304

    • PubMed
    • Google Scholar
15. 1. Cornell M
    2. Myer L

    (2013) Moving beyond gender stereotypes

    The Lancet 382:506.

    https://doi.org/10.1016/S0140-6736(13)61713-4

    • PubMed
    • Google Scholar
16. 1. De Beaudrap P
    2. Rouet F
    3. Fassinou P
    4. Kouakoussui A
    5. Mercier S
    6. Ecochard R
    7. Msellati P

    (2008) CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, côte d'ivoire

    JAIDS Journal of Acquired Immune Deficiency Syndromes 49:70–76.

    https://doi.org/10.1097/QAI.0b013e3181831847

    • PubMed
    • Google Scholar
17. 1. Di Mascio M
    2. Sereti I
    3. Matthews LT
    4. Natarajan V
    5. Adelsberger J
    6. Lempicki R
    7. Yoder C
    8. Jones E
    9. Chow C
    10. Metcalf JA
    11. Sidorov IA
    12. Dimitrov DS
    13. Polis MA
    14. Kovacs JA

    (2006) Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion

    Journal of Virology 80:2665–2674.

    https://doi.org/10.1128/JVI.80.6.2665-2674.2006

    • PubMed
    • Google Scholar
18. 1. EuroSIDA group
    2. Moore AL
    3. Kirk O
    4. Johnson AM
    5. Katlama C
    6. Blaxhult A
    7. Dietrich M
    8. Colebunders R
    9. Chiesi A
    10. Lungren JD
    11. Phillips AN

    (2003) Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited

    JAIDS Journal of Acquired Immune Deficiency Syndromes 32:452–461.

    https://doi.org/10.1097/00126334-200304010-00017

    • PubMed
    • Google Scholar
19. 1. Fatti G
    2. Mothibi E
    3. Meintjes G
    4. Grimwood A

    (2014) Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in south Africa

    PLOS ONE 9:e100273.

    https://doi.org/10.1371/journal.pone.0100273

    • PubMed
    • Google Scholar
20. 1. Hapuarachchi T
    2. Lewis J
    3. Callard RE

    (2013) A mechanistic model for naive CD4 T cell homeostasis in healthy adults and children

    Frontiers in Immunology 4:366.

    https://doi.org/10.3389/fimmu.2013.00366

    • PubMed
    • Google Scholar
21. 1. Hazenberg MD
    2. Hamann D
    3. Schuitemaker H
    4. Miedema F

    (2000) T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock

    Nature Immunology 1:285–289.

    https://doi.org/10.1038/79724

    • PubMed
    • Google Scholar
22. 1. Hazenberg MD
    2. Otto SA
    3. van Rossum AM
    4. Scherpbier HJ
    5. de Groot R
    6. Kuijpers TW
    7. Lange JM
    8. Hamann D
    9. de Boer RJ
    10. Borghans JA
    11. Miedema F

    (2004) Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1

    Blood 104:3513–3519.

    https://doi.org/10.1182/blood-2004-03-0805

    • PubMed
    • Google Scholar
23. 1. Idigbe EO
    2. Audu RA
    3. Iroha EO
    4. Akinsulie AO
    5. Temiye EO
    6. Ezeaka VC
    7. Adetifa IMO
    8. Musa AZ
    9. Onyewuche J
    10. Ikondu SU

    (2010) T-Lymphocyte subsets in apparently healthy nigerian children

    International Journal of Pediatrics 2010:1–7.

    https://doi.org/10.1155/2010/474380

    • Google Scholar
24. 1. IeDEA and COHERE Cohort Collaborations
    2. Anderegg N

    (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

    Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 66:893–903.

    https://doi.org/10.1093/cid/cix915

    • PubMed
    • Google Scholar
25. 1. Institute of Human Virology/Plateau State Specialist Hospital AIDS Prevention in Nigeria Study Team
    2. Aina O
    3. Dadik J
    4. Charurat M
    5. Amangaman P
    6. Gurumdi S
    7. Mang E
    8. Guyit R
    9. Lar N
    10. Datong P
    11. Daniyam C
    12. Kanki P
    13. Abimiku A

    (2005) Reference values of CD4 T lymphocytes in human immunodeficiency virus-negative adult nigerians

    Clinical Diagnostic Laboratory Immunology 12:525–530.

    https://doi.org/10.1128/CDLI.12.4.525-530.2005

    • PubMed
    • Google Scholar
26. 1. International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration
    2. Balestre E
    3. Eholié SP
    4. Lokossue A
    5. Sow PS
    6. Charurat M
    7. Minga A
    8. Drabo J
    9. Dabis F
    10. Ekouevi DK
    11. Thiébaut R

    (2012) Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in west africa

    Aids 26:951–957.

    https://doi.org/10.1097/QAD.0b013e3283528ad4

    • PubMed
    • Google Scholar
27. 1. Kaufmann GR
    2. Zaunders J
    3. Murray J
    4. Kelleher AD
    5. Lewin SR
    6. Solomon A
    7. Smith D
    8. Cooper DA

    (2001) Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling

    AIDS Research and Human Retroviruses 17:147–159.

    https://doi.org/10.1089/08892220150217238

    • PubMed
    • Google Scholar
28. 1. Kelley CF
    2. Kitchen CM
    3. Hunt PW
    4. Rodriguez B
    5. Hecht FM
    6. Kitahata M
    7. Crane HM
    8. Willig J
    9. Mugavero M
    10. Saag M
    11. Martin JN
    12. Deeks SG

    (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment

    Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 48:787–794.

    https://doi.org/10.1086/597093

    • PubMed
    • Google Scholar
29. 1. Lawn SD
    2. Myer L
    3. Bekker LG
    4. Wood R

    (2006) CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan africa

    BMC Infectious Diseases 6:59.

    https://doi.org/10.1186/1471-2334-6-59

    • PubMed
    • Google Scholar
30. 1. Lawrie D
    2. Coetzee LM
    3. Becker P
    4. Mahlangu J
    5. Stevens W
    6. Glencross DK

    (2009) Local reference ranges for full blood count and CD4 lymphocyte count testing

    South African Med. J 99:243–248.

    https://doi.org/10.7196/SAMJ.2745

    • Google Scholar
31. 1. Lawrie D
    2. Payne H
    3. Nieuwoudt M
    4. Glencross DK

    (2015) Observed full blood count and lymphocyte subset values in a cohort of clinically healthy south african children from a semi-informal settlement in cape town

    South African Medical Journal 105:589–595.

    https://doi.org/10.7196/SAMJnew.7914

    • Google Scholar
32. 1. Lewis J
    2. Walker AS
    3. Castro H
    4. De Rossi A
    5. Gibb DM
    6. Giaquinto C
    7. Klein N
    8. Callard R

    (2012) Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution

    Journal of Infectious Diseases 205:548–556.

    https://doi.org/10.1093/infdis/jir787

    • PubMed
    • Google Scholar
33. 1. Lewis J
    2. Payne H
    3. Walker AS
    4. Otwombe K
    5. Gibb DM
    6. Babiker AG
    7. Panchia R
    8. Cotton MF
    9. Violari A
    10. Klein N
    11. Callard RE

    (2017) Thymic output and CD4 T-Cell reconstitution in HIV-Infected children on early and interrupted antiretroviral treatment: evidence from the children with HIV early antiretroviral therapy trial

    Frontiers in Immunology 8:1162.

    https://doi.org/10.3389/fimmu.2017.01162

    • PubMed
    • Google Scholar
34. 1. Lugada ES
    2. Mermin J
    3. Kaharuza F
    4. Ulvestad E
    5. Were W
    6. Langeland N
    7. Asjo B
    8. Malamba S
    9. Downing R

    (2004) Population-based hematologic and immunologic reference values for a healthy ugandan population

    Clinical Diagnostic Laboratory Immunology 11:29–34.

    https://doi.org/10.1128/CDLI.11.1.29-34.2004

    • PubMed
    • Google Scholar
35. 1. Maini MK
    2. Gilson RJ
    3. Chavda N
    4. Gill S
    5. Fakoya A
    6. Ross EJ
    7. Phillips AN
    8. Weller IV

    (1996) Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men

    Sexually Transmitted Infections 72:27–31.

    https://doi.org/10.1136/sti.72.1.27

    • Google Scholar
36. 1. Malaza A
    2. Mossong J
    3. Bärnighausen T
    4. Viljoen J
    5. Newell ML

    (2013) Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverage

    PLOS ONE 8:e70126.

    https://doi.org/10.1371/journal.pone.0070126

    • PubMed
    • Google Scholar
37. 1. Means AR
    2. Risher KA
    3. Ujeneza EL
    4. Maposa I
    5. Nondi J
    6. Bellan SE

    (2016) Impact of age and sex on CD4+ cell count trajectories following treatment initiation: an analysis of the tanzanian HIV treatment database

    PLOS ONE 11:e0164148.

    https://doi.org/10.1371/journal.pone.0164148

    • PubMed
    • Google Scholar
38. 1. Mee P
    2. Fielding KL
    3. Charalambous S
    4. Churchyard GJ
    5. Grant AD

    (2008) Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa

    Aids 22:1971–1977.

    https://doi.org/10.1097/QAD.0b013e32830e4cd8

    • PubMed
    • Google Scholar
39. 1. Moore RD
    2. Keruly JC

    (2007) CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression

    Clinical Infectious Diseases 44:441–446.

    https://doi.org/10.1086/510746

    • PubMed
    • Google Scholar
40. 1. Mutwa PR
    2. Boer KR
    3. Asiimwe-Kateera B
    4. Tuyishimire D
    5. Muganga N
    6. Lange JMA
    7. van de Wijgert J
    8. Asiimwe A
    9. Reiss P
    10. Geelen SPM

    (2014) Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected rwandan children: a prospective study

    PLOS ONE 9:e111948.

    https://doi.org/10.1371/journal.pone.0111948

    • Google Scholar
41. 1. Nakanjako D

    (2016) “Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy (ART) within the IeDEA-East Africa cohort.,”

    AIDS 30:1.

    https://doi.org/10.1097/QAD.0000000000001085

    • Google Scholar
42. 1. Ngowi BJ
    2. Mfinanga SG
    3. Bruun JN
    4. Morkve O

    (2009) Immunohaematological reference values in human immunodeficiency virus-negative adolescent and adults in rural northern Tanzania

    BMC Infectious Diseases 9:1.

    https://doi.org/10.1186/1471-2334-9-1

    • PubMed
    • Google Scholar
43. 1. Oladepo DK
    2. Idigbe EO
    3. Audu RA
    4. Inyang US
    5. Imade GE
    6. Philip AO
    7. Okafor GO
    8. Olaleye D
    9. Mohammed SB
    10. Odunukwe NN
    11. Harry TO
    12. Edyong-Ekpa M
    13. Idoko J
    14. Musa AZ
    15. Adedeji A
    16. Nasidi A
    17. Ya'aba Y
    18. Ibrahim K

    (2009) Establishment of reference values of CD4 and CD8 lymphocyte subsets in healthy nigerian adults

    Clinical and Vaccine Immunology 16:1374–1377.

    https://doi.org/10.1128/CVI.00378-08

    • PubMed
    • Google Scholar
44. 1. Patterson K
    2. Napravnik S
    3. Eron J
    4. Keruly J
    5. Moore R

    (2007) Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy

    HIV Medicine 8:406–410.

    https://doi.org/10.1111/j.1468-1293.2007.00485.x

    • PubMed
    • Google Scholar
45. 1. Pediatric AIDS Clinical Trials Group
    2. Shearer WT
    3. Rosenblatt HM
    4. Gelman RS
    5. Oyomopito R
    6. Plaeger S
    7. Stiehm ER
    8. Wara DW
    9. Douglas SD
    10. Luzuriaga K
    11. McFarland EJ
    12. Yogev R
    13. Rathore MH
    14. Levy W
    15. Graham BL
    16. Spector SA

    (2003) Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric AIDS clinical trials group P1009 study

    The Journal of Allergy and Clinical Immunology 112:973–980.

    https://doi.org/10.1016/j.jaci.2003.07.003

    • PubMed
    • Google Scholar
46. 1. Pinzone MR
    2. Di Rosa M
    3. Cacopardo B
    4. Nunnari G

    (2012) HIV RNA suppression and immune restoration: can we do better?

    Clinical and Developmental Immunology 2012:1–12.

    https://doi.org/10.1155/2012/515962

    • PubMed
    • Google Scholar
47. 1. Prohaska TR
    2. Leventhal EA
    3. Leventhal H
    4. Keller ML

    (1985) Health practices and illness cognition in young, middle aged, and elderly adults

    Journal of Gerontology 40:569–578.

    https://doi.org/10.1093/geronj/40.5.569

    • PubMed
    • Google Scholar
48. Book

    1. R Development Core Team

    (2017)

    R: A Language and Environment for Statistical Computing

    Vienna, Austria: R Foundation for Statistical Computing.

    • Google Scholar
49. 1. Sachsenberg N
    2. Perelson AS
    3. Yerly S
    4. Schockmel GA
    5. Leduc D
    6. Hirschel B
    7. Perrin L

    (1998) Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen

    Journal of Experimental Medicine 187:1295–1303.

    https://doi.org/10.1084/jem.187.8.1295

    • PubMed
    • Google Scholar
50. 1. Schaberg T
    2. Theilacker C
    3. Nitschke OT
    4. Lode H

    (1997) Lymphocyte subsets in peripheral blood and smoking habits

    Lung 175:387–394.

    https://doi.org/10.1007/PL00007585

    • PubMed
    • Google Scholar
51. 1. Sempa JB
    2. Ujeneza EL
    3. Nieuwoudt M

    (2017) Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan africa

    PLOS ONE 12:e0171658.

    https://doi.org/10.1371/journal.pone.0171658

    • PubMed
    • Google Scholar
52. 1. Swiss HIV Cohort Study
    2. Kaufmann GR
    3. Furrer H
    4. Ledergerber B
    5. Perrin L
    6. Opravil M
    7. Vernazza P
    8. Cavassini M
    9. Bernasconi E
    10. Rickenbach M
    11. Hirschel B
    12. Battegay M

    (2005) Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy

    Clin Infect Dis 41:361–372.

    https://doi.org/10.1086/431484

    • PubMed
    • Google Scholar
53. 1. Tsukamoto H
    2. Clise-Dwyer K
    3. Huston GE
    4. Duso DK
    5. Buck AL
    6. Johnson LL
    7. Haynes L
    8. Swain SL

    (2009) Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects

    PNAS 106:18333–18338.

    https://doi.org/10.1073/pnas.0910139106

    • PubMed
    • Google Scholar
54. Software

    1. Ujeneza EL

    (2020) Github “RM_Code_eLife”, version swh:1:rev:624ff31c5fc969885f29b7291ee06886d24c64f7

    Software Heritage.

    https://archive.softwareheritage.org/swh:1:dir:ba7b18cf527d685936238a30dc77727658fdf575;origin=https://github.com/EvaLiliane/RM_Code_eLife;visit=swh:1:snp:87391191e64b09372e55426eaa30efe42b4df33d;anchor=swh:1:rev:624ff31c5fc969885f29b7291ee06886d24c64f7/
55. Book

    1. WHO Multicentre Growth Reference Study Group,

    (2006)

    “WHO Child Growth Standards: Length/height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Indexfor-Age: Methods and Development.”, 312

    Geneva, Switizerland: World Health Organization.

    • Google Scholar
56. 1. Zeh C
    2. Amornkul PN
    3. Inzaule S
    4. Ondoa P
    5. Oyaro B
    6. Mwaengo DM
    7. Vandenhoudt H
    8. Gichangi A
    9. Williamson J
    10. Thomas T
    11. Decock KM
    12. Hart C
    13. Nkengasong J
    14. Laserson K

    (2011) Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in western Kenya

    PLOS ONE 6:e21040.

    https://doi.org/10.1371/journal.pone.0021040

    • PubMed
    • Google Scholar

Author details

1. Eva Liliane Ujeneza

   1. Department of Science and Technology and National Research Foundation, South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa
   2. African Institute for Mathematical Sciences (AIMS), Next Einstein Initiative, Kigali, Rwanda

   Contribution

   Conceptualization, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology

   For correspondence

   ujeneva@gmail.com

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-5760-4847

2. Wilfred Ndifon

   African Institute for Mathematical Sciences (AIMS), Next Einstein Initiative, Kigali, Rwanda

   Contribution

   Software, Formal analysis, Supervision, Validation, Investigation, Methodology

   Competing interests

   No competing interests declared

3. Shobna Sawry

   Harriet Shezi Children’s Clinic, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

   Contribution

   Data curation

   Competing interests

   No competing interests declared

4. Geoffrey Fatti

   1. Kheth’Impilo AIDS Free Living, Cape Town, South Africa
   2. Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

   Contribution

   Data curation

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-6467-662X

5. Julien Riou

   Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

   Contribution

   Data curation

   Competing interests

   No competing interests declared

6. Mary-Ann Davies

   Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

   Contribution

   Conceptualization, Data curation, Project administration

   Competing interests

   No competing interests declared

7. Martin Nieuwoudt

   1. Department of Science and Technology and National Research Foundation, South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa
   2. Institute for Biomedical Engineering (IBE), Stellenbosch University, Stellenbosch, South Africa

   Contribution

   Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration

   Competing interests

   No competing interests declared

8. IeDEA-Southern Africa collaboration

• 731

  views

• 122

  downloads

• 1

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.